# A Study to Evaluate the Long Term Safety and Effectiveness of Novantrone Therapy Followed by Copaxone Treatment for Multiple Sclerosis

> **NCT00203086** · — · COMPLETED · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.** · enrollment: 30 (actual)

## Conditions studied

- Relapsing Remitting Multiple Sclerosis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT00203086
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2009-10
- **Final completion:** 2009-12
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2010-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00203086

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00203086, "A Study to Evaluate the Long Term Safety and Effectiveness of Novantrone Therapy Followed by Copaxone Treatment for Multiple Sclerosis". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00203086. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*